1309365-75-0

Basic information

• Product Name: N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide
• Synonyms: N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide
• CAS NO: 1309365-75-0
• Molecular Weight: 575.532
• Mol File: 1309365-75-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide(1309365-75-0)
• EPA Substance Registry System: N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-3-yl)propanamide(1309365-75-0)

Safety Data

• Hazardous Substances Data: 1309365-75-0(Hazardous Substances Data)

Upstream product

• 1309365-73-8 (E)-3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)-N-(cyclohexylmethyl)acrylamide 
• 1309365-72-7 (E)-methyl 3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)acrylate 
• 1309365-71-6 6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinoline-3-carbaldehyde 
• 1309365-70-5 6-bromo-2-chloro-7-fluoroquinoline-3-carbaldehyde 
• 351-30-4 N-(4-bromo-3-fluorophenyl)ethanamide 
• 1309365-74-9 3-(6-bromo-7-fluoro-2-(4-methoxybenzylamino)quinolin-3-yl)-N-(cyclohexylmethyl)propanamide 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1309365-76-1 N-(cyclohexylmethyl)-3-(7-fluoro-2-(4-methoxybenzylamino)-6-o-tolylquinolin-3-yl)propanamide 
• 1309364-62-2 3-(2-amino-7-fluoro-6-o-tolylquinolin-3-yl)-N-(cyclohexylmethyl)propanamide 

Relevant articles and documents

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer?s disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer?s Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I